Latest Breaking News On - Hilde windels - Page 4 : comparemela.com

Celyad Oncology (CYAD) CEO Issues Letter to Shareholders

Celyad Oncology (CYAD) CEO Issues Letter to Shareholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Van lanschot kempenHilde windelschairHilde windelsFilippo pettiMichel lussiercoMichel lussierCelyad oncology the companyPropharma group holdingsCelyad oncologyCell therapy manufacturing unitNcardia belgium

Celyad Oncology SA: Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights

Enrollment ongoing in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory (r/r) multiple myeloma (MM) In July 2022,

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionFrance generalBruxelles capitaleLincoln parkSara zelkovicMichel lussierLincoln park capital fundExchange commissionCommunications investor relationsInternational financial reporting standardsDrug administrationEuronext nasdaq

Celyad Oncology SA (CYAD) Appoints Hilde Windels as Board Chair

Celyad Oncology SA (CYAD) Appoints Hilde Windels as Board Chair
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Hilde windelsFilippo pettiMichel lussierChief financial officerChief executiveInterim chief executive officerChief executive officerCelyad oncologyInterim chief executive

Celyad Oncology SA: Celyad Oncology Announces Leadership Updates

Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionFrance generalSara zelkovicHilde windelsFilippo pettiMichel lussierExchange commissionCommunications investor relationsRegulatory newsEuronext nasdaqChief financial officerChief executive

Celyad Oncology Announces Leadership Updates

MONT-SAINT-GUIBERT, Belgium, June 24, 2022 (GLOBE NEWSWIRE) Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage.

Mont saint guibertWaals gewestNew yorkUnited statesWalloon regionSara zelkovicHilde windelsFilippo pettiMichel lussierCommunications investor relations directorExchange commissionChief financial officerChief executiveInterim chief executive officerChief executive officerCelyad oncology